---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-078823"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2026-06-29T20:07:30+00:00"
generated_at: "2026-06-29T20:09:25.631907+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "medium"
source: SEC EDGAR
---

# Nuvectis Pharma reduces ATM capacity to $5M and suspends sales under Leerink agreement

## Summary
- On June 29, 2026, Nuvectis lowered the amount available for sale under the Sales Agreement Prospectus to $5 million.
- The company is suspending the Sales Agreement Prospectus and will not sell any shares until a new prospectus or registration statement is filed.
- The Sales Agreement with Leerink Partners LLC remains in full force and effect; only the current offering is paused.

## SEC filing metadata
- accession: 0001104659-26-078823
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2026-06-29T20:07:30+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/0001104659-26-078823-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/tm2618981d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-078823
- JSON: https://secwatch.observer/filing/0001104659-26-078823.json
- Plain text: https://secwatch.observer/filing/0001104659-26-078823.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.